PI3K is a common therapeutic target with existing drugs such as GDC-0941 and LY294002 which are reported to inhibit proliferation in human (Raynaud et al., 2009) and mouse transgenic (Renner et al., 2007) PCa cell lines. This evidence concerns the gene PIK3CB and posterior cortical atrophy.